biotech / news / / Devdiscourse
Danish pharmaceutical giant Novo Nordisk reported an adjusted operating profit of 32.86 billion Danish crowns.
Novo Nordisk's Q1 adjusted operating profit reached 32.86 billion crowns, surpassing projections.
KEY POINTS
- Sales of the new Wegovy weight-loss pill drove Novo's better-than-expected financial results.
- Novo revised its adjusted sales and profit decline outlook to 4%-12%, an improved estimate.
- Novo Nordisk is leveraging Wegovy's success amid new competition from Eli Lilly's Foundayo drug.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →